- Home
- SSTI vs AGEN Comparison
SSTI vs AGEN Comparison
Compare SSTI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSTI
- AGEN
- Stock Information
- Founded
- SSTI 1996
- AGEN 1994
- Country
- SSTI United States
- AGEN United States
- Employees
- SSTI N/A
- AGEN N/A
- Industry
- SSTI Computer Software: Prepackaged Software
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SSTI Technology
- AGEN Health Care
- Exchange
- SSTI Nasdaq
- AGEN Nasdaq
- Market Cap
- SSTI 145.1M
- AGEN 123.6M
- IPO Year
- SSTI 2017
- AGEN 2000
- Fundamental
- Price
- SSTI $10.89
- AGEN $4.10
- Analyst Decision
- SSTI Buy
- AGEN Buy
- Analyst Count
- SSTI 7
- AGEN 2
- Target Price
- SSTI $20.29
- AGEN $14.50
- AVG Volume (30 Days)
- SSTI 63.0K
- AGEN 466.1K
- Earning Date
- SSTI 11-12-2025
- AGEN 11-11-2025
- Dividend Yield
- SSTI N/A
- AGEN N/A
- EPS Growth
- SSTI N/A
- AGEN N/A
- EPS
- SSTI N/A
- AGEN N/A
- Revenue
- SSTI $103,899,000.00
- AGEN $101,706,000.00
- Revenue This Year
- SSTI $11.17
- AGEN $60.49
- Revenue Next Year
- SSTI $9.39
- AGEN N/A
- P/E Ratio
- SSTI N/A
- AGEN N/A
- Revenue Growth
- SSTI 1.47
- AGEN N/A
- 52 Week Low
- SSTI $9.33
- AGEN $1.38
- 52 Week High
- SSTI $19.43
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- SSTI 35.14
- AGEN 45.86
- Support Level
- SSTI $11.01
- AGEN $3.85
- Resistance Level
- SSTI $11.56
- AGEN $4.60
- Average True Range (ATR)
- SSTI 0.38
- AGEN 0.24
- MACD
- SSTI -0.07
- AGEN 0.04
- Stochastic Oscillator
- SSTI 2.52
- AGEN 38.42
About SSTI SoundThinking Inc.
SoundThinking Inc is a public safety technology company that combines transformative solutions and strategic advisory services for law enforcement and civic leadership. Its flagship SafetySmart platform includes ShotSpotter, the acoustic gunshot detection system, CrimeTracer, the foremost law enforcement search engine, CaseBuilder, a one-stop investigation management system, and ResourceRouter, software that directs patrol and community anti-violence resources to help maximize their impact.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).